Drugs Induced Stevens-Johnson Syndrome

Yıl 2010, Cilt: 12 Sayı: 1, 98 - 103, 01.03.2010

Hülya Albayrak Zehra Gürlevik Yusuf Aydın Elif Önder

Öz

Stevens Johnson Syndrome (SJS) is a life threatening mucocutaneous skin disease that mostlydeveloped after using some drug. SJS mostly appear between 2-4th decades. Mucocutaneouslesions were seen between 1-14 days of drug intake. And these lesions spread diffusely all aroundthe body. First treatment choice is the stopping of drug that cause SJS and giving supportingtreatment. After understanding of underlying cytotoxic and immunological mechanism of SJS,new treatment approaches were developed and mortality of disease was reduced. We hereinreport a short review of drug induced SJS and its treatment

Anahtar Kelimeler

Stevens Johnson Syndrome, Drugs.

İlaçlara Bağlı Stevens-Johnson Sendromu

Öz

Stevens Johnson Sendromu (SJS) sıklıkla ilaçlara bağlı olarak gelişen nadir fakat hayatı tehditedebilen mukokutanöz bir cilt reaksiyonudur. Her yaşta ortaya çıkabilmekle birlikte en sık 2–4. dekatlarda görülür. Mukokutanöz lezyonlar, sebep olan ilacın alınmasını takiben 1–14 günlükdöneminin ardından ortaya çıkar. Gövde ve yüzde başlayan eritematöz makülopapülerdöküntüler hızla tüm vücuda yayılır. Tedavisinde ilk basamak, sebep olan ilacın kesilmesi vedestek tedavisidir. Günümüzde altta yatan sitotoksik ve immünolojik mekanizmaların daha iyianlaşılması yeni tedavi yaklaşımlarının ortaya çıkmasını ve mortalitenin azalmasını sağlamıştır.Bu yazıda ilaçlara bağlı olarak gelişen SJS hakkında kısa bir derleme sunulmaktadır

Anahtar Kelimeler

Stevens Johnson Sendromu, İlaçlar

Kaynakça

• Hussain W, Craven NM: Toxic epidermal necrolysis and Stevens-Johnson syndrome. Clin Med. 5:555–558, 2005.
• Stevens AM, Johnson PC: A new eruptive fever assosiated with stomatitis and ophtalmica: report of two cases in children. Am J Dis Child. 24: 526-533, 1922.
• Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC: Clinical classification of cases of toxic epidermal necrolysis, Stevens–Johnson syndrome, and erythema multiforme. Arch Dermatol. 129:92–96, 1993.
• Severino G, Chillotti C, De Lisa R, Del Zompo M, Ardau R: Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann Pharmacother. 39:162–164, 2005.
• Borchers AT, Lee JL, Naguwa SM, Cheema GS, Gershwin ME: Stevens–Johnson syndrome and toxic epidermal necrolysis. Autoimmunity Reviews 7.598–605, 2008.
• Famularo G, De Simone C, Minisola G: Stevens-Johnson syndrome associated with single high dose of lamotrigine in a patient taking valproate. Dermatol Online J.11:25. 2005.
• Levy M, Shear NH: Mycoplasma pneumoniae infections and Stevens Johnson syndrome: report of eight cases and review of the literature. Clin Pediatr.30:42–49, 1991.
• Ravin KA, Rappaport LD, Zuckerbraun NS, Wadowsky RM, Wald ER, Michaels MM: Mycoplasma pneumoniae and atypical Stevens-Johnson syndrome: a case series. Pediatrics. 119:1002–1005, 2007
• Hanno R, Bean SF: Hodgkin’s disease with specific bullous lesions. Am J Dermatopathol. 2:363–366, 1980.
• Margolis RJ, Bhan A, Mihm MC Jr, Bernhardt M: Erythema multiforme in a patient with T cell chronic lymphocytic leukemia. J Am Acad Dermatol. 14:618–627, 1986.
• Hazin R, Ibrahimi OA, Hazin MI, Kimyai-Asadi A: Stevens- Johnson syndrome: Pathogenesis, diagnosis, and management. Ann Medicine. 40:129-1382008.
• Rzany B, Mockenhaupt M, Stocker U, Hamouda O, Schöpf E: Incidence of Stevens Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany. Arch. Dermatol. 129:1059, 1993.
• Roujeau JC: Clinical heterogeneity of drug hypersensitivity. Toxicology. 209:123–129, 2005.
• Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 66:233–243, 1991.
• Iwai K, Miyawaki T, Takizawa T, Konno A, Ohta K, Yachie A, Seki H, Taniguchi N: Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral
• blood lymphocytes, monocytes, and neutrophils. Blood. 84:1201–1208, 1994.
• Nassif A, Moslehi H, Le Gouvello S, Bagot M, Lyonnet L, Michel L, Boumsell L, Bensussan A, Roujeau JC: Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J. Invest. Dermatol. 123:850-855, 2004.
• Nakajima T, Yamanoshita O, Kamijima M, Kishi R, Ichihara G: Generalized skin reactions in relation to trichloroethylene exposure: a review from the viewpoint of drug-metabolizing enzymes. J Occup Health. 45:8–14, 2003.
• Pirmohamed M: Genetic factors in the predisposition to drug- induced hypersensitivity reactions. AAPS J. 8: E20–26, 2006.
• Nassif A, Bensussan A, Dorothee G, Mami-Chouaib F, Bachot N, Bagot M, Boumsell L, Roujeau JC: Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol. 118:728–733, 2002.
• Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M: HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics. 7:813–818, 2006.
• Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 102:4134–4139, 2005.
• Power WJ, Saidman SL, Zhang DS, Vamvakas EC, Merayo- Lloves JM, Kaufman AH, Foster CS: HLA typing in patients with ocular manifestations of Stevens-Johnson syndrome. Ophthalmology. 103:1406–1409, 1996.
• Mukasa Y, Craven N: Management of toxic epidermal necrolysis and related syndromes. Postgrad Med J. 84:60–65, 2008.
• Letko E, Papaliodis DN, Papaliodis GN, Daoud YJ, Ahmed AR, Foster CS: Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol. 94:419-436, 2005.
• Wall V, Yen MT, Yang MC, Huang AJ, Pflugfelder SC: Management of the late ocular sequelae of Stevens-Johnson syndrome. Ocul Surf. 1:192–201, 2003.
• French LE: Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int. 55:9-16, 2006.
• Leaute-Labreze C, Lamireau T, Chawki D, Maleville J, Taieb A: Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson syndrome. Arch Dis Child. 83:347–352, 2000.
• Fritsch PO, Sidoroff A: Drug-induced Stevens Johnson Syndrome/Toxic Epidermal Necrolysis. Am J Clin Dermatol. 1:349-360, 2000.
• Severino G, Chillotti C, De Lisa R, Del Zompo M, Ardau R: Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann Pharmacother.39:162– 164, 2005.
• Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F: Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 333:1600–1607, 1995.
• Sharma VK, Sethuraman G, Minz A: Stevens Johnson syndrome, toxic epidermal necrolysis and SJS-TEN overlap: a retrospective study of causative drugs and clinical outcome. Indian J Dermatol Venereol Leprol. 74: 238-240, 2008.
• Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A: Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 128:35-44, 2008.
• Yamane Y, Aihara M, Ikezawa Z: Analysis of Stevens- Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006.Allergol Int. 56:419-425, 2007.
• Becker DS: Toxic epidermal necrolysis. Lancet. 351:1417– 1420, 1998.
• Metry DW, Jung P, Levy ML: Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. Pediatrics. 112:1430–1436, 2003.
• Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE: Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 282:490–493, 1998.
• Egan CA, Grant WJ, Morris SE, Saffle JR, Zone JJ: Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol. 40:458-461, 1999.
• Patterson R, Dykewicz MS, Gonzalzles A, Gramer LC, Green D, Greenberger PA, McGrath KG, Walker CL: Erythema multiforme and Stevens-Johnson syndrome. Descriptive and therapeutic controversy. Chest. 98:331-336, 1990.
• Yeung CK, Lam LK, Chan HH: The timing of intravenous immunoglobulin therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Exp Dermatol. 30:600-622, 2005.
• Teo L, Tay Y K, Liu T T, Kwok C: Stevens-Johnson syndrome and toxic epidermal necrolysis: efficacy of intravenous immunoglobulin and a review of treatment options. Singapore Med J. 50:29-33, 2009.
• Khalili B, Bahna SL: Pathogenesis and recent therapeutic trends in Stevens- Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol. 97:272-280, 2006.
• Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, Maignan M, Schuhmacher MH, Milpied B, Pilorget A, Bocquet H, Brun-Buisson C, Revuz J: Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 352:1586-1589, 1998.